Showing results (11-20 of 413) with videos related to
Sort By:
Pageof 42
Chinese Clinical Oncology|October 11, 2024
Phase I trials of single-agent new drugs in head and neck cancer: a scoping reviewDaria Maria Filippini, Gregoire Marret, Etienne Bastien, et al.JNCI Cancer Spectrum|April 28, 2020
Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell CarcinomaPaul Gougis, Camille Moreau Bachelard, Maud Kamal, et al.Bulletin Du Cancer|May 5, 2011
[Prevention strategies for brain metastases from HER2-positive breast cancer]Christophe Le TourneauExpert Opinion on Investigational Drugs|July 12, 2008
Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitorChristophe Le Tourneau, Lillian L SiuCancers|July 2, 2021
Drug Development in Tissue-Agnostic IndicationsPauline du Rusquec, Christophe Le TourneauHematology/Oncology Clinics of North America|November 18, 2008
Molecularly targeted agents in the treatment of recurrent or metastatic squamous cell carcinomas of the head and neckChristophe Le Tourneau, Eric X ChenTranslational Oncology|March 14, 2026
Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementationDaria Maria Filippini, Christophe Le TourneauFrontiers in Oncology|March 1, 2019
Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular TargetsEsma Saada-Bouzid, Christophe Le TourneauCurrent Opinion in Oncology|April 9, 2008
Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neckChristophe Le Tourneau, Lillian L SiuCurrent Opinion in Oncology|April 4, 2024
The potential roles of antibody-drug conjugates in head and neck squamous cell carcinomaDaria Maria Filippini, Christophe Le TourneauPageof 42